Monday, May 5, 2014

The Motley Fool: After Missing Earnings, Is Pfizer a Good Value?

When Pfizer (NYSE: PFE  ) last reported earnings I was pretty ambivalent about the stock, and since that late January piece the shares have lagged both the broader market and pharma industry peers like Merck, Lilly, and Novartis. It's not as though the company has been sitting still either, what with positive clinical updates on its Prevnar vaccine and palbociclib oncology drug. Dwarfing all of that is the potential megadeal for British pharma company AstraZeneca (NYSE: AZN  ) . Pfizer needs to guard against overpaying in this potential deal, but these shares are getting closer to an interesting entry point for long-term investors.

Read the full article here:
After Missing Earnings, Is Pfizer a Good Value?

No comments: